Oncolytic viruses induce tumor cell death and antitumor immune memory in the GL261 orthotopic mouse glioma model

Introduction and Aim: Glioblastoma Multiforme is a WHO grade IV neoplasm and is the most frequent primary brain tumor in adults. In spite of current multimodal treatment the prognosis remains poor, with a median overall survival of 14.6 months and a mortality rate of 88% within 3 years. At time of relapse (which is universal), the prognosis is particularly dismal with reports of 100% mortality within 1.5 years. In view of these discouraging results, (pre)clinical research is focused on long-term and tumor-specific treatments, such as oncolytic virotherapy. Not only do oncolytic viruses have the potential to lowe…